EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Hydrocortisone Aceponate for Chronic Otitis: Long‐Term Efficacy

C Lorente-Méndez iD, D Alonso-Miguel iD

Veterinary Dermatology · 2025-12 · 36 (6) · 870-878

DOI: 10.1111/vde.70008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Veterinary Dermatology, online erschienen am 04.08.2025. Verfasst von C Lorente-Méndez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Animal Medicine and Surgery, Veterinary Medicine School, Complutense University of Madrid, Madrid, Spain. Hauptthemen laut MEDLINE: Hydrocortisone, Dog Diseases, Otitis Externa, Anti-Inflammatory Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Effective management of otitis externa (OE) requires addressing all contributing factors to prevent chronicity and recurrence. Evidence on the long‐term efficacy of topical corticosteroids in preventing recurrence and secondary infections remains limited.

Objectives

This retrospective noncontrolled study evaluated the efficacy of hydrocortisone aceponate (HCA) in resolving non‐infectious chronic or recurrent (CR)‐OE with or without proliferative changes, and preventing recurrence of acute episodes and secondary infections. Animals A total of 63 owned dogs (115 ears) with unilateral or bilateral non‐infectious CR‐OE were included. Most ears were enrolled after resolving infectious otitis, as persistent inflammation or recurrence required further management. Materials and Methods Clinical records from two dermatology referral centres (February 2022–July 2023) were reviewed. Dogs were included if they had recurrent otitis for over a year (≥ 1 year) or chronic otitis (≥ 1 month). Otitis severity was assessed using the Otitis Index Score (OTIS3) scale, and by grading stenosis and hyperplasia severity. Enrolled patients received HCA 0.584 mg/mL at weight‐adjusted doses. A reactive phase continued until OTIS3 < 2, followed by a proactive phase with regimens adapted to otitis severity. Concurrent treatments were recorded.

Results

Recurrence was not observed in 79.1% of ears (mean follow‐up 202.6 days). Among 24 relapsed ears, 29.17% recurred after treatment discontinuation. Higher recurrence was associated with stopping therapy ( p < 0.001) and recent bacterial otitis ( p = 0.015). No adverse effects were noted. Conclusions and Clinical Relevance The use of HCA appears to be an effective and safe option for reactive and proactive management of non‐infectious CRC‐OE, reducing recurrences and improving patient and owner quality‐of‐life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydrocortisoneDog DiseasesOtitis ExternaAnti-Inflammatory AgentsRetrospective StudiesAnimalsMaleFemaleDogsChronic DiseaseTreatment OutcomeRecurrence

Stichwörter der Autor:innen

caninechronic otitis externahydrocortisone aceponateproactive treatmentreactive treatmentrecurrent otitis externa

Substanzen

Hydrocortisonehydrocortisone aceponateAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Animal Medicine and Surgery, Veterinary Medicine School, Complutense University of Madrid, Madrid, Spain.
  • LABOKLIN GmbH & Co. KG, Bad Kissingen, Germany.

ORCID-Profile: C Lorente-Méndez, D Alonso-Miguel

Zitieren

APA

Lorente-Méndez, C., & Alonso-Miguel, D. (2025). Hydrocortisone Aceponate for Chronic Otitis: Long‐Term Efficacy. Veterinary Dermatology, 36(6), 870-878. https://doi.org/10.1111/vde.70008

Vancouver

Lorente-Méndez C, Alonso-Miguel D. Hydrocortisone Aceponate for Chronic Otitis: Long‐Term Efficacy. Veterinary Dermatology. 2025;36(6):870-878. doi:10.1111/vde.70008

BibTeX
@article{LorenteMndez2025,
  author = {Lorente-Méndez, C and Alonso-Miguel, D},
  title = {Hydrocortisone Aceponate for Chronic Otitis: Long‐Term Efficacy},
  journal = {Veterinary Dermatology},
  year = {2025},
  volume = {36},
  number = {6},
  pages = {870--878},
  doi = {10.1111/vde.70008}
}
Kostenlos starten →